European Medicines Agency
Evaluation of Medicines for Human Use

London, 4th May 2007
EMEA/181739/2007

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
APRIL 2007 PLENARY MEETING
MONTHLY REPORT

The Committee for Medicinal Products for Human Use (CHMP) held its April plenary meeting from 23-26 April 2007.

Centralised procedure

Initial applications for marketing authorisation

The CHMP adopted five positive opinions by consensus and one by majority (see Circadin) on initial marketing authorisation applications at this meeting:

First accelerated assessment concluded

The CHMP has adopted a positive opinion recommending the granting of a marketing authorisation for the first medicinal product for human use that has been evaluated by the new accelerated assessment procedure.

- **Soliris** (eculizumab), from Alexion Europe SAS, is intended to reduce haemolysis (destruction of red blood cells) in patients with paroxysmal nocturnal haemoglobinuria (PNH). This is a rare blood disorder, in which the red blood cells are weak and are destroyed more rapidly than normal, causing the urine to turn red or dark during an episode (or paroxysm) of haemolysis. Soliris is the **37th orphan medicinal** product to receive a positive CHMP opinion. EMEA review began on 25 October 2006 with an active review time of 147 days. A separate press release is available here.

Other positive opinions

- **Circadin** (melatonin), from Neurim Pharmaceuticals EEC Ltd, intended for the short-term treatment of primary insomnia in patients aged 55 or older. EMEA review began on 26 October 2005 with an active review time of 209 days.

- **Invega** (paliperidone), from Janssen-Cilag International NV, intended for the treatment of schizophrenia in adults. EMEA review began on 24 May 2006 with an active review time of 202 days.

- **Optaflu** (influenza vaccine [surface antigen, inactivated, prepared in cell culture]), from Novartis Vaccine and Diagnostics GmbH & Co. KG, intended for prevention of seasonal influenza in adults. EMEA review began on 19 July 2006 with an active review time of 202 days.

- **Pergoveris** (follitropin alfa and lutropin alfa), from Serono Europe Ltd, intended for the stimulation of follicular development in women with severe luteinising hormone (LH) and follicle stimulating hormone (FSH) deficiency. EMEA review began on 29 March 2006 with an active review time of 208 days.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

- **Siklos** (hydroxycarbamide), from Addmedica SAS, intended to prevent vaso-occlusive crisis, a painful complication of sickle cell syndrome in paediatric and adult patients. Siklos is the **38th orphan medicinal product** to receive a positive opinion. EMEA review began on 26 October 2005 with an active review time of 208 days.

Negative opinions

The CHMP adopted two negative opinions by consensus recommending the refusal of a marketing authorisation for:

- **Cerepro** (adenovirus-mediated *Herpes simplex* virus-thymidine kinase gene), from Ark Therapeutics Ltd. Cerepro is a designated orphan medicinal product intended for the treatment of patients with operable high-grade glioma.

- **Genasense** (oblimersen), from Genta Development Ltd, intended for the treatment of advanced or metastatic melanoma.

Summaries of opinion for these medicinal products are available on the EMEA website http://www.emea.europa.eu/htms/human/opinion/opinion.htm. Further information will be included in the European Public Assessment Report (EPAR) once the European Commission has granted final approval.

Separate question and answer documents explaining the grounds for the negative opinions are available for Cerepro and for Genasense.

Extensions of indication and other recommendations

The CHMP gave six positive opinions by consensus for applications for extensions of indication, adding new treatment options for the following previously approved medicines:

- **Humira** and **Trudexa** (adalimumab), from Abbott Laboratories, to extend the indication to include treatment of adult patients with severe active Crohn's disease. Humira and Trudexa are currently authorised for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

- **Renagel** (sevelamer), from Genzyme B.V., to extend the indication to include the control of hyperphosphataemia in adult patients on peritoneal dialysis. Renagel is currently indicated for the control of hyperphosphatemia in adult patients on haemodialysis.

- **Pegintron** and **Viraferonpeg** (peginterferon alfa-2b), from Schering Plough Europe, to extend the indication of these medicines to include the treatment of adult patients with hepatitis C-infection who have not been treated previously and who have clinically stable HIV co-infection. It is recommended that peginterferon alfa-2b in this indication be used in combination with Rebetol. (see also 'New contraindications')

- **Rebetol** (ribavirin), from Schering Plough Europe, to extend the indication of the medicine to include the treatment of adult patients with hepatitis C-infection who have not been treated previously and who have clinically stable HIV co-infection. Rebetol must be used in combination with peginterferon alfa-2b in this indication. (see also 'New contraindications')

New contraindications

The CHMP also recommended by consensus the addition of a new contraindication for **Pegintron** and **Viraferonpeg (**peginterferon alfa-2b), from Schering Plough Europe, that treatment of hepatitis C should not be initiated in patients with hepatitis C and HIV co-infection who have cirrhosis and a Child-Pugh score of 6 or higher. As **Rebetol,** also from Schering Plough Europe, is used in combination with peginterferon alfa-2b to treat hepatitis C in patients with hepatitis C and HIV co-infection, this contraindication will also be mentioned in the product information of Rebetol.

Deletion of an indication

The CHMP recommended by consensus that the indication for **Visudyne** (verteporfin), from Novartis Europharm Ltd, in the treatment of occult subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) be deleted, following evaluation of new data showing that the efficacy was insufficient to maintain it.
Visudyne is still indicated to treat patients with:

- exudative (wet) AMD with predominantly classic subfoveal CNV,
- subfoveal CNV secondary to pathological myopia.

Summaries of opinions for these medicinal products are available and can be found here.

Withdrawals

The Committee was informed by Insmed Incorporated of its decision to withdraw their application for a centralised marketing authorisation for the medicinal product Iplex (mecasermin rinfabate), 60 mg/ml (36 mg) solution for injection. More information is available in the press release and further details about Iplex and its current state of scientific assessment at the time of withdrawal will be made available in a question and answer document. This document, together with the withdrawal letter from the company, will be published on the EMEA website http://www.emea.europa.eu/humandocs/Humans/EPAR/iplex in the very near future.

Lists of Questions

The Committee adopted five Lists of Questions on initial applications (two under the mandatory scope, and three under the optional scope including one generic application) and two Lists of Questions on "line extensions" applications (in accordance with Annex II of Commission Regulation (EC) No. 1085/2003.

Detailed information on the centralised procedure

An overview of centralised procedures since 1995 is given in **Annex 1**. The post-authorisation centralised procedures finalised during this meeting are summarised in **Annex 2**. The list of medicinal products for which marketing authorisations have been granted by the European Commission since the CHMP plenary meeting in March 2007 is provided in **Annex 3.**

Applications for marketing authorisation for orphan medicinal products

Details of those orphan medicinal products that have been subject of a centralised application for marketing authorisation since the March 2007 CHMP plenary meeting are provided in **Annex 4**.

Referral procedures

Referral procedure concluded

Concluding a referral procedure for **Cefuroximaxetil 125 omhulde tabletten 125 mg, Cefuroximaxetil 250 omhulde tabletten 250 mg, Cefuroximaxetil 500 omhulde tabletten 500 mg,** (cefuroxim [as axetil]), from Sandoz B.V., the Committee recommended that a marketing authorisation for the treatment of mild to moderately severe infections caused by micro-organisms susceptible to cefuroxime be granted, but that the medicines should not be used in the treatment of uncomplicated gonorrhoea.
The referral procedure was initiated under Article 29 of the Community Code on medicinal products for human use (Directive 2001/83/EC). This type of procedure is initiated because of disagreements between the EU Member States in the context of the mutual-recognition procedure.

Referral procedures started

The CHMP started a number of referral procedures under Article 29 of the Community Code on medicinal products for human use (Directive 2001/83/EC):

- **Xeomin** (Clostridium botulinum type A neurotoxin complex), from Merz Pharmaceuticals GmbH
- **Bicaluplex 150mg tablet** (Bicalutamide), from Ingers Industrial Solutions s.r.o.
- **Menitorix** (Hib/MenC conjugate vaccine), from GlaxoSmithKline Biologicals.

Mutual Recognition procedure and Decentralised procedures-Human

The CHMP noted the report from the 17th CMD(h) (Co-ordination Group for Mutual Recognition and Decentralised procedures-Human) held on 23-24 April 2007. For further details, please see the relevant press release on the CMD(h) website under the heading Press Releases: http://www.hma.eu/

CHMP Working Parties

The CHMP was informed of the outcome of the discussions of the Scientific Advice Working Party (SAWP) meeting, which was held on 28-30 March 2007. For further details, please see **Annex 5**.

Documents prepared by the CHMP Working Parties adopted during the April 2007 CHMP meeting are listed in **Annex 6**.

Name Review Group (NRG)

Statistical information on the outcome of the checking of acceptability of proposed invented names for medicinal products processed through the centralised procedure is provided in **Annex 7**.

Upcoming meetings following the April 2007 CHMP plenary meeting:

- The 33rd meeting of the CHMP will be held at the EMEA on 21-24 May 2007.
- The next Invented Name Review Group meeting will be held at the EMEA on 21st May 2007.
- The 18th CMD(h) (Co-ordination Group for Mutual Recognition and Decentralised Procedures) will be held at the EMEA on 21-23 May 2007.
- A SAG Oncology meeting will take place on the 11th May 2007.
- A SAG Anti-Infectives meeting will take place early July 2007.

Organisational matters

The main topics addressed during the April 2007 CHMP meeting related to:

- The election of Dr. Pavlovic-Ganascia as Vice-Chair for the Scientific Advice Working Party.
- The election of Dr. Brasseur as Chair for the Vaccine Working Party.
- The outcome of the training on assessment of pandemic influenza dossiers held at the end of January where 78 attendees from 23 countries attended the two days EMEA training. Further training will be organised in 2008.
- Follow-up discussion regarding the draft agenda for the workshop on the "Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products" to be held on 12 June 2007.
- Discussion on criteria to be followed when requesting one additional 5-year renewal for centrally authorised products (EMEA/131973/2006). The Committee adopted this reflection paper which will be transmitted to the European Commission prior to its release for one month public consultation.
- Follow-up discussion regarding the therapeutic areas in the mandatory scope of the centralised procedure as of 20th May 2008.

- Discussion on the report on WHO-GHAVE consultation on "Preparing for HIV vaccine efficacy trial results" meeting held 14-15 March 2007 in Geneva.
- Follow-up discussion with regards to research areas that could benefit from European Commission funding as part of the 2007 Work Programme for the Health Theme of the 7th Framework Programme.
- Discussion on the peer review experience gained from April 2005 to March 2007.
- Discussion on the SCENIHR preliminary report on the appropriateness of the EU Technical Guidance Documents for chemicals in regard to nanomaterials.

PROCEDURAL ANNOUNCEMENT

As part of the implementation of the procedure for the review of information on medicinal products by Patients'/Consumers' Organisations (PCOs), from the May 2007 CHMP meeting, the EMEA will be involving experts from PCOs in the review of new EPAR summaries as well as in the review of Package Leaflets at the time of the renewal of the marketing authorisation.

Information on the involvement on PCOs in the review of product information can be found here and the Standard Operating Procedure describing the preparation of EPAR Summaries can be found here.

Noël Wathion
Head of Unit
Post-Authorisation Evaluation of Medicines for Human Use, Tel. (+44-20) 74 18 85 92

This CHMP Monthly Report and other documents are available on the Internet at the following address:
http://www.emea.europa.eu

ANNEX 1 TO CHMP MONTHLY REPORT APRIL 2007

PRE-AUTHORISATION: MARKETING AUTHORISATION APPLICATIONS

Activity	2007								1995 onwards
	Optional Scope				Mandatory scope			Total	Overall total
	NAS	Significant innovation	Interest of Patients	Generics	Biotech	Indications	Orphans		
Applications for MA submitted	7	2	0	1	10	1	2	23	598
Positive opinions	7	1	0	0	4	2	1	15	394
Negative opinions[1]	0	0	0	0	1	1	0	2	14
Withdrawals prior to opinion	2	0	0	0	1	0	1	4	107
Marketing authorisation granted by the Commission	9	1	0	0	2	4	2	18	383

PRE-AUTHORISATION: SCIENTIFIC SERVICES

Activity (submissions)	2007	1995 onwards
Compassionate use applications	0	0
Art. 58 applications	1	4
Consultation for medical devices[2]	1	3
PMF (Click here for a list of PMF certifications)	0	10
VAMF	0	0

[1] In case of Re-examination under Art. 9(2) of Regulation (EC) No. 726/2004, the opinion will not be counted twice.
[2] Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as regards medical devices incorporating stable derivates of human blood or plasma and Directive 2001/104/EC

OUTCOME OF THE APRIL 2007 CHMP MEETING IN RELATION TO ACCELERATED ASSESMENT PROCEDURES

Substance	Intended indications(s)	Accelerated Assessment Requests	
		Accepted	Rejected
Biological	N/A	N/A	N/A
Chemical	Treatment of HIV-1 infection	X	

ANNEX 2 TO CHMP MONTHLY REPORT APRIL 2007

POST-AUTHORISATION: TYPE I AND II VARIATIONS, ANNEX II, RENEWALS AND ANNUAL RE-ASSESSMENT APPLICATIONS

Activity	2007	Overall total 1995 onwards
Type I Variations (positive notifications)	278	4473
Type II Variations (positive opinions)	279	3141
Type II Variations (negative opinions)	0	8
Annex II Applications (positive opinions)	10	152
Annual Re-assessment (positive opinions)	12	-
Opinion for renewals of conditional MA's (positive opinions)	0	0
5 Year Renewals (positive opinions)	19	-

Opinions for Type II Variation applications	
Number of Opinions	**Outcome**
6 Extensions of indication	6 Positive opinions
21 SPC changes	21 Positive opinions
30 Quality changes	30 Positive opinions

Opinions for Annual Re-Assessment applications		
Name of Medicinal Product (INN) MAH	**Outcome**	**Comments**
Naglazyme (galsulfase) BioMarin Pharmaceutical Inc	Positive Opinion	The Marketing Authorisation will remain under exceptional circumstances.

Opinion for renewals of conditional MA's		
Name of Medicinal Product (INN) MAH	**Outcome**	**Comments**
N/A	N/A	N/A

Opinions for 5 Year Renewal applications		
Name of Medicinal Product (INN) **MAH**	**Outcome**	**Comments**
Tamiflu (oseltamivir) Roche Registration Ltd	Positive Opinion adopted	The Committee agreed that a further 5-year renewal would be required
Cystagon (mercaptamine) Orphan Europe SARL	Positive Opinion adopted	Unlimited validity
Neorecormon (epoetin beta) Roche Registration Ltd	Positive Opinion adopted	Unlimited validity
Pegasys (peginterferon alfa-2a) Roche Registration Ltd	Positive Opinion adopted	Unlimited validity
Revasc (desirudin) Canyon Pharmaceuticals Ltd A	Positive Opinion adopted	Unlimited validity

ANNEX 3 TO CHMP MONTHLY REPORT APRIL 2007

MEDICINAL PRODUCTS GRANTED A COMMUNITY MARKETING AUTHORISATION UNDER THE CENTRALISED PROCEDURE SINCE THE MARCH 2007 CHMP MONTHLY REPORT

Invented Name	Daronrix
INN	A/Viet Nam/1194/2004 (H5N1) whole virus inactivated antigen
Marketing Authorisation Holder	GlaxoSmithKline Biologicals S.A
Proposed ATC code	J07BB01
Indication	Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
CHMP Opinion date	24.01.2007
Marketing Authorisation Date	21.03.2007

Invented Name	Advagraf
INN	tacrolimus
Marketing Authorisation Holder	Astellas Pharma GmbH
Proposed ATC code	L04AA05
Indication	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
CHMP Opinion date	22.02.2007
Marketing Authorisation Date	23.04.2007

Invented Name	Docetaxel Winthrop
INN	docetaxel
Marketing Authorisation Holder	Aventis Pharma S.A
Proposed ATC code	L01CD02
Indication	Breast cancer Docetaxel Winthrop (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel Winthrop (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

	Docetaxel Winthrop (docetaxel) monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel Winthrop (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel Winthrop (docetaxel) in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Docetaxel Winthrop (docetaxel) is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. Docetaxel Winthrop (docetaxel) in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Docetaxel Winthrop (docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric Adenocarcinoma Docetaxel Winthrop (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Docetaxel Winthrop (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck
CHMP Opinion date	22.02.2007
Marketing Authorisation Date	20.04.2007

Invented Name	Toviaz
INN	fesoterodine
Marketing Authorisation Holder	Schwarz Pharma AG
Proposed ATC code	G04BD11
Indication	Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
CHMP Opinion date	22.02.2007
Marketing Authorisation Date	20.04.2007

OVERVIEW OF DESIGNATED ORPHAN MEDICINAL PRODUCTS THAT HAVE BEEN THE SUBJECT OF A CENTRALISED APPLICATION FOR MARKETING AUTHORISATION: UPDATE SINCE THE MARCH 2007 CHMP MEETING

Active substance	**Sponsor/applicant**	**EU Designation Number & Date of Orphan Designation**	**Designated Orphan Indication**
Ambrisentan (Volibris)	Glaxo Group Limited-UK	EU/3/05/ 27311/04/2005	Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hyperetension

PRE-AUTHORISATION: SCIENTIFIC ADVICE AND PROTOCOL ASSISTANCE EMEA CENTRALISED PROCEDURES

	1995 - 2006	2007	Overall Total
Scientific Advice	718	46	764
Follow-up to Scientific Advice	127	11	138
Protocol Assistance	157	17	174
Follow-up to Protocol Assistance	40	9	49
	1042	**83**	**1125**

OUTCOME OF THE APRIL 2007 CHMP MEETING IN RELATION TO SCIENTIFIC ADVICE PROCEDURES

Final Scientific Advice Procedures

Substance	**Intended indications(s)**	**Type of Request**				**Topic**			
		New		**Follow-up**		**Pharmaceutical**	**Pre-clinical**	**Clinical**	**Significant Benefit**
		SA	**PA**	**SA**	**PA**				
Biological	Treatment of diabetes mellitus			X			X		
Biological	Treatment of Rheumatoid Arthritis	X					X	X	
Biological	Treatment of emphysema				X			X	X
Biological	Treatment of renal anemia			X				X	
Chemical	Diagnosis of glioma		X					X	X
Chemical	Treatment of chronic obstructive pulmonary disease	X					X	X	
Biological	Treatment of renal cell carcinoma		X			X			
Chemical	Treatment of ovarian cancer		X					X	X

Substance	Intended indications(s)	Type of Request				Topic			
		New		Follow-up		Pharmaceutical	Pre-clinical	Clinical	Significant Benefit
		SA	PA	SA	PA				
Chemical	Treatment of pulmonary arterial hypertension				X			X	
Biological	Prevention of congenital cytomegalovirus infection		X					X	
Biological	Prevention of invasive disease caused by Neisseria meningitidis			X				X	
Chemical	Treatment of adult chronic HCV infection	X				X			
Chemical	Treatment of Alzheimer's disease			X				X	
Chemical	Treatment of autoimmune uveitis		X				X	X	X
Chemical	Treatment of Congenital or Aphakic Glaucoma	X						X	
Biological	Treatment of macular edema secondary to Type I or Type II diabetes mellitus	X						X	
Chemical	Treatment of congenital adrenal hyperplasia		X					X	X

SA: Scientific Advice
PA: Protocol Assistance

The above-mentioned 5 Scientific Advice letters, 6 Protocol Assistance letters, 4 Follow-up Scientific Advice letters and 2 Follow-up Protocol Assistance letters were adopted at the 23-26 April CHMP meeting.

New requests for Scientific Advice Procedures

The Committee accepted 18 new Requests for which the procedure started at the SAWP meeting held on 28-30 March 2007. The new requests are divided as follows: 12 Initial Scientific Advice, 5 Follow-up Scientific Advice and 1 Follow-up Protocol Assistance.

DOCUMENTS PREPARED BY THE CHMP WORKING PARTIES ADOPTED DURING THE APRIL 2007 CHMP MEETING

GENE THERAPY WORKING PARTY (GTWP)

Reference number	Document	Status[3]
CHMP/GTWP/367513/ 2006	Concept paper on the development of a Guideline on clinical monitoring and follow-up of patients exposed to gene therapy/gene transfer medicinal products	Adopted for 3 months public consultation
CHMP/GTWP/125459/ 2006	Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products	Adopted for 6 months public consultation

QUALITY WORKING PARTY (QWP)

Reference number	Document	Status[3]
EMEA/140443/2007	Question and Answer on residual solvents	Adopted.
CHMP/CVMP/QWP/1054 31/2007	Corrected guideline on stability testing: stability testing of existing active substances and related finished products	Adopted.

EFFICACY WORKING PARTY (EWP)

Reference number	Document	Status[3]
CHMP/EWP/122355/2007	Concept paper on preparation of an addendum to the guideline on development of antibacterial agents to specifically address the clinical development of new agents to treat tuberculosis	Adopted for 3-month public consultation
CHMP/EWP/156308/2007	Concept paper on the clinical development of medicinal products for the treatment Hepatitis C infection	Adopted for 3-month public consultation
CHMP/EWP/182695/2007	Concept paper on Proposal for revision of ICH E7 guideline regarding adequacy of guidance on the elderly	Adopted.
EMEA/CHMP/EWP/ 117085/2007	Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease	Adopted in March 2007 for 6-month public consultation but will now be further revised prior to the public consultation phase

[3] Adopted or release for consultation documents can be found at the EMEA website (under "What's new-recent publications" or under Human Medicines-Guidance documents").

INVENTED NAME REVIEW GROUP (NRG)

	April 2007		2007	
	Accepted	Rejected	Accepted	Rejected
Proposed invented names [1]	7	7	45	46
Justification for retention of invented name *	1	5	7	9

*In case of objections to the proposed invented name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMEA website.

[1]Five proposed invented name requests have been postponed from the April NRG meeting

	April 2007		2007	
	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	16	14	98	87
Criterion - Safety concerns				
Similarity with other Invented name	13	11	80	68
Conveys misleading therapeutic/pharmaceutical connotations	1	0	3	0
Misleading with respect to composition	1	0	1	0
Criterion - INN concerns				
Similarity with INN	1	2	3	3
Inclusion of INN stem	0	0	0	2
Criterion - Other public health concerns				
Unacceptable qualifiers	0	0	0	1
Conveys a promotional message	0	1	8	11
Appears offensive or has a bad connotation	0	0	0	2
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	3	0
Similarity between name of prodrug and related active substance	0	0	0	0

See *Guideline on the Acceptability of Invented names for human medicinal products processed through the Centralised procedure (CPMP/328/98)* for detailed explanations of criteria used.